None listed
Conditions
Interventions
Drug : In addition to existing antidepressants(SSRI, SNRI, or NDRI), Benzodiazepine(Depending on the equivalent capacity of each type) will be given orally 1 to 3 times per day for 8 weeks to the cont
Sponsors
Chung-Ang Univerisity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? the age between 18 and 65 ? people diagnosed with major depressive disorder without psychotic features by the Structured Clinical Interview for DSM-5 (SCID-5) ? Beck Anxiety Inventory(BAI) scale score of 16 or higher (with moderate or severe anxiety symptoms) ? based on the baseline, those who have no history of taking Mirtazapine or Benzodiazepine in the last 2 months ? people who have been administered antidepressants(SSRI, SNRI, or NDRI) in stable doses for more than 1 month.
Exclusion criteria
Exclusion criteria: ? people diagnosed with other psychiatric disorders by SCID-5-CV ? People with severe medical conditions (cancer, heart failure, renal failure, liver disease, lung disease, thyroid disease, and acute inflammatory conditions) ? people who have a history of substance dependence or misuse in the past or present ? people with a history of epilepsy, head injury, or organic mental disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beck Anxiety Inventory(BAI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Beck Depressive Inventory(BDI-II);Korean Symptom Check List 95 (KSCL95);Clinical Global Impression- Severity of illness (CGI-S) & Clinical Global Impression of Improvement (CGI-I);Quantitative Electroencephalogram(QEEG);functional Near-Infrared Spectroscopy(fNIRS) | — |
Countries
Korea, Republic of
Contacts
Public ContactDa Seul Kim
Chung-Ang University
Outcome results
None listed